**CALL FOR ABSTRACT FROM GENERAL PEDIATRICIANS**

**ANNOUNCEMENT**

We are launching for the first-time oral case presentation by general pediatrician in pediatric hematology and oncology conference. This gives General Pediatricians the opportunity to present interesting cases in hematology and oncology you come across at initial presentation or during management and you think other pediatricians can learn from it.

By presenting your abstract, you will highlight best practices and educate pediatricians on how they can involve effectively in the care of children with cancer and hematology problems. We can arrange pediatric hematologist and oncologist to support your case presentation and discussion.

Therefore, the committee is pleased to invite abstracts for case presentation from general pediatrician for the

**4th Emirates Pediatric Hematology & Oncology** that will take place on **24-25 September 2021** as a hybrid conference at the **Conrad Abu Dhabi Etihad Towers Hotel, UAE**.

Participants are encouraged to show real life examples of cases and practical take-away message.

**ABSTRACT TOPICS**

Submissions are welcome in all areas of pediatric hematology & oncology but not limited to:

* *Hypochromic, microcytic anemia*
* *Acute to severe anemia*
* *Iron deficiency anemia*
* *Thalassemia*
* *Clotting disorders in children*
* *Cervical lymphadenopathy*
* *Childhood cancer presentation*

**GENERAL SUBMISSION GUIDELINES**

Please do read the following guidelines thoroughly.

For any additional questions, please contact EPHOC Event Coordinator [jan@menaconference.com](mailto:jan@menaconference.com)

|  |  |
| --- | --- |
| **DEADLINE** | * Abstracts must be submitted by ***31st July, 2021*** * Authors can edit their abstracts until the submission deadline. No further changes will be accepted after the date. * The committee reserves the right to extend or shorten the date of abstract submission. |
| **SUBMISSION** | * Preferably, all abstracts must be submitted online on the [**abstract submission platform**](https://forms.office.com/Pages/ResponsePage.aspx?id=DQSIkWdsW0yxEjajBLZtrQAAAAAAAAAAAAN__iDb7Q9UNzYxTUJUUUg1TUZLS09aUURZVlk5TklTWi4u)[**(CLICK HERE)**](https://forms.office.com/Pages/ResponsePage.aspx?id=DQSIkWdsW0yxEjajBLZtrQAAAAAAAAAAAAN__iDb7Q9UNzYxTUJUUUg1TUZLS09aUURZVlk5TklTWi4u) * Alternatively, (1) asbtracts can be submitted to MENA Conference website or (2) by email to [jan@menaconference.com](mailto:jan@menaconference.com) * Abstracts received not following the standard formats will not be accepted. * For any issues on the online platform, please contact [jan@menaconference.com](mailto:jan@menaconference.com) |
| **ACKNOWLEDGEMENT** | * Abstract submission will be acknowledged via email. If there is no acknowledgement received within a week of the submission or if you have any additional queries, please contact [jan@menaconference.com](mailto:jan@menaconference.com) |
| **NOTIFICATION OF RESULTS** | * All abstract submitters will be notified of the outcome via email on ***10th August, 2021*** by the Event Coordinator (jan@menaconference.com) * The email will contain information on acceptance or rejection of abstract. * For accepted oral presenters, the date and time of the assigned session will be communicated to you as soon as the committee has finalized the agenda. |
| **LANGUAGE** | * All documents must be submitted and presented in **English language**. * It is the author’s responsibility to submit the correct abstract (grammatically and scientifically) |
| **TYPE OF PRESENTATION** | * Accepted abstracts are scheduled for oral presentation however, the final decision on the type of presentation lies within the abstract review committee. |
| **ABSTRACT SPECIFICS** | * A maximum of 2 abstracts can be submitted per author * Abstracts must follow maximum word count as indicated. Do not include names of specific individuals, institutions, pharmaceutical companies, or specific manufacturers in the body of the abstract. * Figures and tables are not yet to be included in the submission of abstract. * Abstracts must include sufficient information for reviewers to judge the nature and significance of the topic, the adequacy of the investigative strategy, the nature of the results, and the conclusions. * The abstract should summarize the substantive results of the work and not merely list topics to be discussed. * Abstracts must contain original scientific data collected by the author(s). All reports must be based on work that has already been completed. No studies "in progress" will be accepted. |
| **AUTHOR** | * Only the main author (1) is allowed to present the abstract at the conference * The presenting author (main author) must be clearly marked on the submission form with his contact information * Kindly provide up-to-date contact details and any changes in the presenter must be communicated as soon as possible to [jan@menaconference.com](mailto:jan@menaconference.com) |
| **PRESENTER INFORMATION** | * Only one presenter is allowed to present the abstract. Kindly make note of this for abstracts with multiple authors * Due to COVID-19 guidelines and travel restrictions, accepted abstracts whose main author resides from outside UAE are asked to do a virtual presentation. * The selected abstract / presenter AND all authors will receive:   + complimentary registration   + Certificate of attendance (CME certificate)   + Appreciation certification for presenting at the conference |
| **ABSTRACT REVIEW PROCESS** | Abstracts are to be reviewed by the scientific committee of EPHOC2021 |
| **ABSTRACT SELECTION PROCESS** | Criteria will include uniqueness of case, appropriateness of methods, interpretation and presentation of results, overall clarity ***(10th August, 2021)*** |

Thank you for taking interest to present at the

**4th Emirates Pediatric Hematology and Oncology Conference**

***For Further enquiries, please contact JAN*** [***jan@menaconference.com***](mailto:jan@menaconference.com) ***| 971 24919888 | 971 565033782***